Peripheral LCN2 has been evaluated and established as a biomarker for kidney injury [15] but was also proposed as a potential blood-based biomarker for intestinal inflammation [16] and Alzheimer’s disease [17]. Here, LCN2 is linked to early-onset autosomal dominant Alzheimer disease.